Standard of care CD19-targeting CAR-T therapy for Relapsed-Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) faces frequent resistance often driven by regulatory T cell (Treg) activation. This study identifies Timosaponin AIII (TAIII) as A2AR inhibitor for enhanced CAR-T activity while depleting CAR-Treg formation.
- Mingqi Hou
- Wenjun Zhang
- Jing Yang
